FibroGen (FGEN) Misses Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
FibroGen Reports First Quarter 2023 Financial Results
May 8, 2023 4:01 PM EDTÂ Topline Data From Four Phase 3 Trials Expected Through 3Q 2023
 Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value
Entered Into Exclusive License for FOR46 with Fortis Therapeutics
SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2023 and provided an update on the companys recent developments.
We look forward to reporting topline data from four pivotal phase 3 trials through the... More
